研究

Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, and Kazuhiko Nakagawa

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung CancerHER3 Augmentation via Blockade of EGFR/AKT Signaling.

Hidetoshi Hayashi, Kimio Yonesaka, Atsushi Nakamura, Daichi Fujimoto, Koichi Azuma, Shinya Sakata, Motoko Tachihara, Satoshi Ikeda, Toshihide Yokoyama, Osamu Hataji, Yukihiro Yano, Katsuya Hirano, Haruko Daga, Hideaki Okada, Yasutaka Chiba, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

Kohsuke Isomoto, Koji Haratani, Takahiro Tsujikawa, Yusuke Makutani, Hisato Kawakami, Masayuki Takeda, Kimio Yonesaka, Kaoru Tanaka, Tsutomu Iwasa, Hidetoshi Hayashi, Akihiko Ito, Kazuto Nishio, Kazuhiko Nakagawa

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.

Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda & Kazuhiko Nakagawa

Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

Hisato Kawakami, Kazuhiro Nishikawa, Toshio Shimokawa, Kazumasa Fujitani, Shigeyuki Tamura, Shunji Endo, Michiya Kobayashi, Junji Kawada, Yukinori Kurokawa, Akira Tsuburaya, Takaki Yoshikawa, Junichi Sakamoto, Taroh Satoh

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

Yusuke Makutani, Hisato Kawakami, Takahiro Tsujikawa, Kanako Yoshimura, Yasutaka Chiba, Akihiko Ito, Junichiro Kawamura, Koji Haratani, Kazuhiko Nakagawa

Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer

Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, Hayashi H, Sakai K, Chiba Y, Tsuya A, Goto H, Otsuka E, Okida H, Kobayashi M, Yoshimoto R, Funabashi M, Hashimoto Y, Hirotani K, Kagari T, Nishio K, Nakagawa K.

HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K.

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).

Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H.

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.

Suzuki S, Haratani K, Hayashi H, Chiba Y, Tanizaki J, Kato R, Mitani S, Kawanaka Y, Kurosaki T, Hasegawa Y, Okabe T, Tanaka K, Akashi Y, Ozaki T, Nishio K, Ito A, Nakagawa K.

Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.